Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/011001METHOD FOR ANTIGEN DETECTION FROM DIRECT CLINICAL SAMPLES
WO 13.01.2022
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
Appl.No PCT/US2021/040672 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor RODWELL, Timothy
In one aspect, the disclosure relates to test strips for detecting and/or monitoring the treatment of a disease in a subject. The test strips are inexpensive and disposable and can be used directly with clinical biological samples from patients including, but not limited to, blood, plasma, saliva, and urine. Also disclosed are methods of using the test strips to quantify antigens produced by a virus or microorganism causing an infectious disease. The methods can be conducted at a point of care for a patient and do not require expensive equipment or extensive operator training. The methods are also rapid to complete and can be used to monitor progress in the treatment of a disease This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
2.WO/2022/005412A METHOD FOR OBTAINING IMMUNE PLASMA
WO 06.01.2022
Int.Class A61K 35/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
Appl.No PCT/TR2020/050788 Applicant OVALI, Ercüment Inventor OVALI, Ercüment
The invention relates to a method involving pathogen inactivation, extraction, and pooling of plasma collected from different donors with COVID19 PCR RNA test negative, COVID IgG positive and COVID IgM negative test results in addition to previous COVID19 laboratory evidence; and the pathogen-free, concentrated, pooled COVID19 immune plasma products obtained by this method.
3.WO/2022/003530NEUTRALIZING ANTIBODIES TO SARS CORONAVIRUS-2
WO 06.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IB2021/055755 Applicant FONDAZIONE TOSCANA LIFE SCIENCES Inventor ANDREANO, Emanuele
The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against SARS-CoV-2. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 dependent diseases.
4.WO/2021/260602HYPERIMMUNE GLOBULINS FOR TREATMENT AND PREVENTION OF COVID-19
WO 30.12.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/IB2021/055578 Applicant EMERGENT BIOSOLUTIONS CANADA INC. Inventor DROBIC, Bojan
The present disclosure is directed to compositions comprising a mixture of anti-SARS-CoV-2 immune globulins and/or antigen-binding fragments thereof and methods of using the same to treat or prevent a SARS-CoV-2 infection or COVID-19.
5.WO/2021/260692COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASE CAUSED BY CORONAVIRUS
WO 30.12.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/IL2021/050759 Applicant KAMADA LTD. Inventor AYALON, Michal
Provided herein are compositions comprising human polyclonal antibodies and methods of using same for treating or preventing coronavirus infections and diseases, disorders and symptoms associated with coronavirus infection.
6.WO/2021/262672SARS-COV-2 RBD CONSTRUCTS
WO 30.12.2021
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
Appl.No PCT/US2021/038411 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor SCHIEF, William
The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.
7.WO/2021/258190PAN-EBOLAVIRUS MONOCLONAL ANTIBODY
WO 30.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CA2021/050827 Applicant HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF HEALTH Inventor QUI, Xiangguo
The immune-elicited pan-ebolavirus m Ab, known as 4F9, recognizes multiple ebolavirus GPs, and neutralizes GP-expressing recombinant viruses as well as authentic ebolaviruses. The broadly neutralizing antibody (b NAb) provided protection against at least one ebolavirus in animal models. Furthermore, a cocktail of 4F9 with a second b NAb conferred superior protection against EBOV in guinea pigs.
8.WO/2021/258625ANTI-SAR-COV-2 (COVID-19) FULLY HUMANIZED MONOCLONAL ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 30.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/129881 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor WAN, Xiaochun
The present invention provides an anti-SAR-COV-2 antibody, or an antigen-binding fragment thereof, and an application thereof, having a heavy chain complementary determining region as shown in SEQ ID Nos: 1-3, and a light chain complementary determining region as shown in SEQ ID Nos: 4-6. The antibody of the present invention is a humanized antibody, and has a low side effect, and high affinity and specificity.
9.WO/2021/262040USE OF A GLUTARIMIDE DERIVATIVE FOR TREATING DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY
WO 30.12.2021
Int.Class A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Appl.No PCT/RU2021/050170 Applicant LTD “VALENTA-INTELLEKT” Inventor NEBOLSIN, Vladimir Evgenievich
The present invention relates to medicine and concerns the treatment of diseases associated with aberrant Interleukin-6 activity and the development of cytokine release (cytokine storm) syndrome, preferably the treatment of COVID-19, as well as other diseases complicated by aberrant Interleukin-6 activity and the development of cytokine release syndrome, using the compound 1-(2-(1-methyl-1Н-imidazol-4-yl)ethyl)piperidine-2,6-dione (formula I). The invention provides for the creation of a novel effective drug for treating diseases associated with the development of cytokine release syndrome.
10.113845588一种抗猪轮状病毒的卵黄抗体的制备方法及其用途
CN 28.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202110577755.8 Applicant 西南民族大学 Inventor 张斌
本发明公开了一种抗猪轮状病毒的卵黄抗体的制备方法,包括如下步骤:注射免疫本发明制备的RVA灭活疫苗,连续免疫4次,每次间隔2周,2免后,当抗体中和效价达到1:200以上时认为免疫合格,每天收集鸡蛋,做好标记,4℃保存备用,提取卵黄抗体IgY。本发明方法制备得到的卵黄抗体对仔猪RVA的预防、治疗均有一定的效果,且能显著的缩短病程,可用于制备检测、预防和/或治疗猪轮状病毒感染引起的相关疾病的产品。